Search research articles
Contact Us
Filters
Showing results (61-70 of 66) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 66 results.
British Journal of Haematology
|
May 7, 2021
Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis
Alexandros Rampotas, Matthew R Wilson, Oliver Lomas, et al.
Leukemia & Lymphoma
|
October 16, 2023
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma
Georg Hess, Martin Dreyling, Lucie Oberic, et al.
Blood
|
November 14, 2023
Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib
Alex Rampotas, Luke Carter-Brzezinski, Tim C P Somervaille, et al.
Science Translational Medicine
|
July 1, 2026
CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis
Alexandros Rampotas, Zoë C Wong, Isaac Gannon, et al.
British Journal of Haematology
|
May 3, 2026
Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom
Alexandros Rampotas, Gabriel Naylor-Layland, Clare Brown, et al.
Blood Advances
|
December 21, 2023
Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study
Ann Tivey, Rohan Shotton, Toby A Eyre, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 66) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 66 results.
British Journal of Haematology
|
May 7, 2021
Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis
Alexandros Rampotas, Matthew R Wilson, Oliver Lomas, et al.
Leukemia & Lymphoma
|
October 16, 2023
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma
Georg Hess, Martin Dreyling, Lucie Oberic, et al.
Blood
|
November 14, 2023
Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib
Alex Rampotas, Luke Carter-Brzezinski, Tim C P Somervaille, et al.
Science Translational Medicine
|
July 1, 2026
CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis
Alexandros Rampotas, Zoë C Wong, Isaac Gannon, et al.
British Journal of Haematology
|
May 3, 2026
Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom
Alexandros Rampotas, Gabriel Naylor-Layland, Clare Brown, et al.
Blood Advances
|
December 21, 2023
Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study
Ann Tivey, Rohan Shotton, Toby A Eyre, et al.
Page
of 7